Targeted blockade of both CD47 and PD-L1 on tumor cells with a bispecific anti-PD-L1-SIRPα agent showed significantly enhanced tumor targeting and therapeutic efficacy comparing with monotherapy [89]. This evidence concerns the gene SIRPA and neoplasm.